Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
-
New hope for FSHD: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called AOC 1020 for people with FSHD, a genetic disease that causes muscle weakness. About 84 adults who completed a previous study will receive the drug through an IV. The main goal is to check for side effects…
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 05:29 UTC
-
Hope for muscle disease: new drug enters final testing phase
Disease control OngoingThis study tests a new medicine called AOC 1001 for people with myotonic dystrophy type 1, a genetic disease that causes muscle weakness and stiffness. About 159 adults with a confirmed diagnosis will receive either the drug or a placebo by IV. The main goal is to see if the drug…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Hope for DM1: new drug tested for long-term safety
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effects of a drug called AOC 1001 in people with myotonic dystrophy type 1 (DM1), a genetic muscle disease. About 230 adults who already took part in earlier AOC 1001 studies will receive the drug intravenously. The main goal is to tra…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 11, 2026 20:49 UTC